StratDeck

Two stocks in Healthcare

Haleon vs Oxford Biomedica: profit, growth, debt and price compared

Haleon is stronger on 4 of 6 figures: profit margin, debt, price for its expected profit and price trend. Oxford Biomedica is stronger on 1: sales growth.

Figures as of 18 November 2026Yahoo Finance
Explore Haleon's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Haleon and Oxford Biomedica side by side
HaleonHLN.LOxford BiomedicaOXB.L
Net marginStronger: 14.6%−23.2%
Revenue growth, past year+2.20%Stronger: +9.00%
Debt to equityStronger: 50.2%273.1%
Forward P/EStronger: 15.4×Loss
Dividend yield2.13%—
AnalystsBuy · 18Buy · 8
From its 200-day averageStronger: −3.3%−5.2%

Share price over the past year

  • Haleon−7.1%
  • Oxford Biomedica−13.2%

20 Nov 202518 Nov 2026

Haleon or Oxford Biomedica: which is stronger?

  • HLN.L

    Which is more profitable?

    Haleon keeps more of each sale as profit: 14.6% against −23.2%.

  • OXB.L

    Which is growing its sales faster?

    Oxford Biomedica is growing its sales faster: +9.00% over the past year, against +2.20%.

  • HLN.L

    Which has borrowed less?

    Haleon has borrowed less: its debt is 50.2% of what its shareholders own, against 273.1% for Oxford Biomedica.

  • HLN.L

    Which costs less for the profit it is expected to make?

    Haleon is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.

  • Which pays more in dividends?

    Haleon pays 2.13% a year in dividends for what a share costs, where Oxford Biomedica pays none.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • HLN.L

    Which is in the stronger price trend?

    Haleon's price is in the stronger trend: 3.3% below its 200-day average, against 5.2% below.

What each company does

HLN.LHaleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Reports results on 25 February 2027

OXB.LOxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Reports results on 25 March 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every UK healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.